- Kaleido is one of the world’s smallest and lightest insulin patch pumps, with a low ecological footprint due to its reusable design
- Paired with the Diabeloop DBLG1 control software and Dexcom G6 CGM sensor, it serves as a world class Hybrid Closed Loop Insulin dosing system, improving users’ Time in Range glucose values by 16.7%1
- Kaleido can be worn as a patch on the body or carried in the pocket. DBLG1 requires only four parameters for setup after which it’s self-learning
November 21, Utrecht, The Netherlands
ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest insulin patch pump systems for managing type 1 diabetes, is pleased to announce the launch of a Hybrid Closed Loop system for automated insulin delivery. This system delivers insulin by using the DBLG1 algorithm, which receives input from the Dexcom G6 Continuous Glucose Monitoring (CGM) sensor. It combines the convenience of the Kaleido insulin pump with two market-leading innovations designed by Diabeloop and Dexcom to create a Hybrid Closed Loop system for managing type 1 diabetes which is flexible, self-learning and easy to use.
Frans Cromme, Chief Executive Officer of ViCentra, said: “We aim to deliver the best user experience as well as excellent clinical results with our Kaleido insulin pump and our partners. Kaleido with DBLG1 and Dexcom G6 improves users’ Time in Range by 16.7%1, an achievement that should bring real benefits to people with type 1 diabetes. We are proud to deliver this game changing technology via a beautiful and small device, as we feel people deserve this when they need to rely on a medical device 24/7.”
Inge Van Boxelaer, endocrinologist at AZ St-Lucas Ghent hospital, remarked: “I love seeing ViCentra trying to make these people’s lives a little better. If I were a person with diabetes, I would be incredibly open to such a small, innovative and cheerfully coloured Kaleido insulin pump which is perfectly formed and discreet.”
Nienke Rutgers, a person with Type 1 diabetes, commented: “Kaleido gives me an undisturbed life and is flexible in all situations during the day. I can wear it directly on my body and I do not notice it. Being even less preoccupied with diabetes is great, I do not have to focus on the condition, and I can get on with daily activities. It is super nice also that Kaleido comes with a well-known product like DBLG1.”
Kaleido users can wear their pump as a patch or place it in their pocket at their own discretion. The system comes with two durable pumps that are rechargeable, eliminating the need to dispose of the pump every 3 days as other patch pumps do. It is available in 10 bright colours and provides the ability to pause or take the pump off for intermittent breaks.
Diabeloop’s DBLG1 is a system deploying a well-known algorithm that is used by 10,000+ users2 in Europe already. The system draws on real-time glucose data, reducing hypoglycaemia by more than 50%3 and using personalised parameters and self-learning to adjust Kaleido’s insulin delivery for an optimised management of type 1 diabetes. DBLG1 algorithm considers the user’s glucose levels provided by the Dexcom G6 Continuous Glucose Monitor (CGM) alongside inputs on meals and activities to determine the insulin delivery. Users and healthcare professionals have real-time access to their data insights via automated transfer to the cloud platform YourLoops.
ViCentra is launching the Hybrid Closed Loop system in Germany, the Netherlands and France with its commercial partner Diabeloop. Roll-out to additional countries which include the UK and Italy is planned for 2024.
Stephane Majerus, Chief Executive Officer of Diabeloop, commented: “We are proud to extend our partnership with ViCentra, home of Kaleido, offering people with type 1 diabetes a new level of options in the management of their diabetes. This alliance between Diabeloop’s algorithm technology and the ViCentra pump aims to offer people with diabetes the benefits of the Kaleido design combined with our highly performing and proven algorithm. Diabeloop’s ultimate goal remains to make available the most advanced solutions to improve the quality of life of people with diabetes, enabling them to devote more time to their passions and daily lives.”
Contact for media enquiries:
Optimum Strategic Communications
Richard Staines, Zoe Bolt, Katie Flint
Tel: +44 (0)20 3882 9621
Notes to Editors
ViCentra B.V., with headquarters in Utrecht, the Netherlands develops, manufactures and markets next generation insulin patch pumps and for insulin delivery for people with type 1 diabetes. The company’s flagship product is the Kaleido insulin pump which is CE marked and commercially available in Europe. It is one of the world’s smallest, lightest insulin pump systems, waterproof, available in 10 colour combinations and is available both as a manual and a Hybrid Closed Loop System. ViCentra was founded in 2013 and is backed by INKEF Capital, EQT Life Sciences, Health Innovations, Invest-NL, Partners in Equity, and Kreos Capital. More information about ViCentra can be found at www.hellokaleido.com.
About DBLG1 with Kaleido – Hybrid Closed Loop System
With a simple setup procedure using only four different parameters and no need for a fingerstick test*, the cutting-edge Hybrid Closed Loop System saves time for healthcare professionals by providing 24/7 insights with automatic data transfer sharing with care teams, linked to the cloud (YourLoops), providing infinite possibilities for its users. The different tube lengths allow the user to wear the pump as a patch or place in the pocket and is available in a range of assorted colours, providing a pump which is personalized to each user. With a modular design, the Kaleido pump is also designed to be more sustainable, with two reusable pumps and a reusable handset. Infusion sets and cartridges can be changed separately when it is convenient for the user, at least every 3 days.
Diabeloop’s mission: Making innovation accessible to people living with diabetes, improving clinical results while relieving them of their constant mental burden.
Created in 2015, Diabeloop offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop’s Hybrid Closed Loop algorithm integrated in a dedicated handset, is a CE-marked medical device under MDR standards and distributed in Europe. Today, Diabeloop gathers the personality, passion, and skills of talented individuals who work hard to improve the quality of life for every person living with diabetes. More information about Diabeloop can be found at www.diabeloop.com.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
- Amadou, Coralie, Sylvia Franc, Pierre-Yves Benhamou, Sandrine Lablanche, Erik Huneker, Guillaume Charpentier, and Alfred Penfornis. 2021. “Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-Up.” Diabetes Care 44(3):844–46. doi: 10.2337/dc20-1809. ↩︎
- English Portal – Diabeloop: interoperable self-learning diabetes management solutions (cea.fr) ↩︎
- Benhamou, Pierre-Yves, Alice Adenis, Yousra Tourki, Sylvie Pou, Stéphanie Madrolle, Sylvia Franc, Dulanjalee Kariyawasam, Jacques Beltrand, David C. Klonoff, and Guillaume Charpentier. 2022. “Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System.” Journal of Diabetes Science and Technology 193229682211285. doi: 10.1177/19322968221128565. ↩︎